Globus Medical (GMED) : The consensus on Globus Medical (GMED) based on 11 analyst recommendation on the company stock is 2.18, which is interpreted as a Buy recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 5 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 5 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating. 1 analyst also believes that the downside risk to the stock is higher and suggests a Sell on Globus Medical (GMED).
Globus Medical (GMED) stock is expected to deviate a maximum of $3.24 from the average target price of $26.75 for the short term period. 8 Street Experts have initiated coverage on the stock with the most promising target being $33 and the most muted being $23.
For the current week, the company shares have a recommendation consensus of Buy. Globus Medical (NYSE:GMED): The stock opened at $23.22 on Thursday but the bulls could not build on the opening and the stock topped out at $23.34 for the day. The stock traded down to $23.07 during the day, due to lack of any buying support eventually closed down at $23.11 with a loss of -0.34% for the day. The stock had closed at $23.19 on the previous day. The total traded volume was 249,523 shares.
In a related news, The director, of Globus Medical Inc, Liptak Robert had unloaded 15,300 shares at $27.5 per share in a transaction on January 4, 2016. The total value of transaction was $420,750. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.
Globus Medical, Inc. is a medical device company. The Company is focused on developing products for patients with musculoskeletal disorders and spine disorders. Its products consist of two categories: Innovative Fusion and Disruptive Technologies. Innovative Fusion products comprise fusion products to treat various spinal disorders for the entire spine and can be used in various surgical approaches. Disruptive Technologies represents a shift in the treatment of spinal disorders by allowing for surgical procedures and the treatment of spinal disorders. The Companys portfolio of Disruptive Technology products includes products that allow for minimally invasive surgical (MIS) techniques, as well as treatment alternatives, including motion preservation technologies, such as dynamic stabilization, total disc replacement and interspinous process spacer products, and biomaterials technologies, as well as interventional pain management solutions.